Shares in Zealand Pharma soared 34% on Monday after an experimental weight-loss drug it is developing with Boehringer Ingelheim yielded what they called "groundbreaking".
2 drugs nearing approval to know: Optum beckershospitalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from beckershospitalreview.com Daily Mail and Mail on Sunday newspapers.
1. In this randomized controlled trial, among patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis, resmetirom was superior to placebo in improving fibrosis. 2. Diarrhea and nausea were the most common adverse events associated with resmetirom. Evidence Rating Level: 1 (Excellent) Study Rundown: NASH is a progressive liver disease associated with metabolic dysfunction characterized by
Dublin, Feb. 13, 2024 (GLOBE NEWSWIRE) The "Nonalcoholic Steatohepatitis (NASH) Patient Pool Analysis, Market Size and Market Forecast APAC - 2034" report has been added to ResearchAndMarkets.com's offering.This report comprises of detailed understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted patient burden, treatment addressable patient population, as well as key differences in market trends in the APAC region (India, China, South Korea, Taiwan, and Australia)